Aerska key facts
- Developer of RNA medicines designed to treat, delay, and prevent diseases of the brain.
- It has raised $60.0M; the latest was Early Stage VC ($39.0M) in Feb 2026.
- Notable investors include Entrepreneurs First, Speedinvest, BlueYard Capital, EQT Life Sciences, Norrsken VC — 15 tracked in total.
- Status: Privately Held (backing).
Who backs Aerska
15+Membership and data by Private Market View
- ·The complete investor list: 15 names
- ·Watch Aerska: the Monday email on marks, rounds and moves
Aerska funding rounds
No funding rounds for Aerska are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Aerska investors
15 investors are on record for Aerska, including Entrepreneurs First, Speedinvest, BlueYard Capital and EQT Life Sciences. By type, the record holds 4 venture capital firms and 1 hedge fund.
About Aerska
Developer of RNA medicines designed to treat, delay, and prevent diseases of the brain. The company silences the genes that cause harm, aims to preserve minds, protect memories, and enable our loved ones to live healthy and long lives, and offers unprecedented potency, durability, and precision for hitting disease targets at their origin, intracellularly, enabling healthcare professionals to provide effective care and improve patient outcomes.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2025
- Employees
- 21
- Website
- aerska.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Aerska doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.